Взаимосвязь FoxP3+ регуляторных т-клеток с активностью заболевания и уровнем антител при раннем ревматоидном артрите

Автор: Авдеева А.С., Рубцов Ю.П., Дыйканов Д.Т., Попкова Т.В., Насонов Е.Л.

Журнал: Научно-практическая ревматология @journal-rsp

Статья в выпуске: 3 т.55, 2017 года.

Бесплатный доступ

Цель - проанализировать взаимосвязь количества FoxP3+ регуляторных Т-клеток (Трег) с клинико-лабораторными показателями активности заболевания и уровнем антител в группе пациентов с ранним ревматоидным артритом (РА). Материал и методы. В исследование были включены 45 не получавших ранее терапии метотрексатом пациентов с ранним РА (критерии ACR/EULAR 2010 г.), в том числе 39 женщин; медиана возраста составила 52,0 [32,5; 57,5] года, длительность заболевания - 5 [4; 6] мес, DAS28 - 5,01 [4,18; 5,8]; 71,1% больных были позитивны по ревматоидному фактору (РФ) и 88,9% позитивны по антителам к циклическому цитруллинированному пептиду (АЦЦП). Относительное и абсолютное количество Трег (FoxP3+CD25+; CD152+surface; CD152+intracellular; FoxP3+CD127-; CD25+CD127-; FoxP3+ICOS+; FoxP3+CD154+; FoxP3+CD274+) определялось методом иммунофлюоресцентного окрашивания и многоцветной проточной цитофлюориметрии. Контрольную группу составили 20 здоровых доноров, сопоставимых по полу и возрасту с обследованными больными. Результаты и обсуждение. У 22 (48,9%) больных была высокая, у 20 (44,4%) - умеренная и у 3 (6,7%) - низкая активность патологического процесса по DАS28. У пациентов с ранним РА, по сравнению со здоровыми донорами, отмечалось более низкое процентное количество (ПК) FoxP3+CD25+ клеток, ПК и абсолютное содержание (абс.) FoxP3+ICOS+ клеток, ПК и абс. FoxP3+CD154+ и FoxP3+ CD274+ Т-клеток; pрег при раннем РА, что ассоциируется с более высокой активностью заболевания, наличием системных проявлений болезни, а также сопровождается гиперпродукцией антител.

Еще

Ранний ревматоидный артрит, активность заболевания, аутоантитела, регуляторные т-лимфоциты

Короткий адрес: https://sciup.org/14945818

IDR: 14945818 | DOI: 10.14412/1995-4484-2017-245-251

Список литературы Взаимосвязь FoxP3+ регуляторных т-клеток с активностью заболевания и уровнем антител при раннем ревматоидном артрите

Быковская СН, Насонов ЕЛ. Роль дефектов иммуносупрессии в развитии аутоиммунных заболеваний. Научно-практическая ревматология. 2005;43(4):81-4
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T Cells and immune tolerance. Cell. 2008;133(5):775-87 DOI: 10.1016/j.cell.2008.05.009
Zeng H, Chi H. The interplay between regulatory T cells and metabolism in immune regulation. OncoImmunology. 2013;2(11):e26586. Epub 2013 Oct 21 DOI: 10.4161/onci.26586
Lahl K, Loddenkemper C, Drouin C, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med. 2007;204(1):57-63. Epub 2007 Jan 2 DOI: 10.1084/jem.20061852
Buckner JH. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849-59 DOI: 10.1038/nri2889
Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun. 2005;25 Suppl:56-62 DOI: 10.1016/j.jaut.2005.04.008
Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331
Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-61 DOI: 10.1038/nature01661
Cope A. T cells in rheumatoid arthritis. Arthr Res Ther. 2008;10 Suppl 1:S1 DOI: 10.1186/ar2412
Choy E. Selective modulation of T cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:510-8.
Steward-Tharp S, Song Y, Siegel R, O’Shea J. New insights into T cells biology and T cells directed therapy for autoimmunity inflammation and immunosuppression. Ann NY Acad Sci. 2010;1183:123-48 DOI: 10.1111/j.1749-6632.2009.05124.x
Cao D, Malmstrom V, Baecher-Allan C, et al. Isolation and functional characterization of regulatory CD25brightCD4+ T cells fromthe target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003;33:215-23 DOI: 10.1002/immu.200390024
Cao D, van Vollenhoven R, Klareskog L, et al. CD25+CD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthr Res Ther. 2004;6:R335-R346 DOI: 10.1186/ar1192
Van Amelsfort JMR, Jacobs KMG, Bijlsma JWJ, et al. CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004;50:2775-85 DOI: 10.1002/art.20499
Mottonen M, Heikkinen J, Mustonen L, et al. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exper Immunol. 2005;140:360-7 DOI: 10.1111/j.1365-2249.2005.02754.x
Liu M-F, Wang C-R, Fung L-L, et al. The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. Scand J Immunol. 2005;62:312-7 DOI: 10.1111/j.1365-3083.2005.01656.x
Cao D, Borjesson O, Larsson P, et al. FOXP3 identifies regulatory CD25brightCD4+ T cells in rheumatic joints. Scand J Immunol. 2006;63:444-52 DOI: 10.1111/j.1365-3083.2006.001755.x
Jiao Z, Wang W, Jia R, et al. Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol. 2007;36:428-33 DOI: 10.1080/03009740701482800
Moradi B, Schnatzer P, Hagmann S, et al. CD4+CD25+/highCD127low/-regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints -analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res Ther. 2014;16: R97 DOI: 10.1186/ar4545
Dejaco C, Duftner C, Klauser A, Schirmer M. Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatic. Rheumatol Int. 2010;30:297-303 DOI: 10.1007/s00296-009-0949-9
Sempere-Ortells JM, Perez-Garcia V, Marin-Alberca G, et al. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity Score-28. Autoimmunity. 2009;42:636-45 DOI: 10.3109/08916930903061491
Kawashiri S-Y, Kawakami A, Okada A, et al. CD4+CD25(high)CD127(low/-) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2517-21 DOI: 10.3899/jrheum.110283
Han GM, O’Neil-Andersen NJ, Zurier RB, Lawrence DA. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008;253:92-101 DOI: 10.1016/j.cellimm.2008.05.007
Lin SC, Chen K-H, Lin C-H, et al. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. 2007;37:987-96 DOI: 10.1111/j.1365-2362.2007.01882.x
Ji L, Geng Y, Zhou W, Zhang Z. A study on relationship among apoptosis rates, number of peripheral T cell subtypes and disease activity in rheumatoid arthritis. Int J Rheum Dis. 2016;19:167-71 DOI: 10.1111/1756-185X.12211
Dombrecht EJ, Aerts NE, Schuerwegh AJ, et al. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. Clin Exper Rheumatol. 2006;24:31-7.
Lawson CA, Brown AK, Bejarano V, et al. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford). 2006;45(10):1210-7 DOI: 10.1093/rheumatology/kel089
Hensor RMA, Hunt L, Patmar R, et al. Predicting the evaluation of inflammatory arthritis in ACPA-positive individuals: can T-cell subset help? Ann Rheum Dis. 2014;73 Suppl 1:A14 DOI: 10.1136/annrheumdis-2013-205124.32
Ehrenstein MR, Evans JG, Singt A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J Exp Med. 2004;200(3):277-85. Epub 2004 Jul 26 DOI: 10.1084/jem.20040165
McGovern JL, Nguyen DX, Notley CA, et al. Th17 cells are restarained by T reg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 2012;64(10):3129-38 DOI: 10.1002/art.34565
Wehrens EJ, Mijnheer G, Duurland CL, et al. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood. 2011;118:3538-48 DOI: 10.1182/blood-2010-12-328187
Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 DOI: 10.1002/art.27500
Behrens F, Himsel A, Rehart S, et al. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1151-6 DOI: 10.1136/ard.2006.068320
Kim CH, Rott LS, Clark-Lewis I, et al. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med. 2001;193:1373-81 DOI: 10.1084/jem.193.12.1373
Odegard JM, Marks BR, DiPlacido LD, et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med. 2008;205:2873-86 DOI: 10.1084/jem.20080840
Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006;6:741-50 DOI: 10.1038/nri1886
Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral Immunity due to long-lived plasma cells. Immunity. 1998;8:363-72 DOI: 10.1016/S1074-7613(00)80541-5
Hoyer BF, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/Wmice. J Exp Med. 2004;199:1577-84 DOI: 10.1084/jem.20040168
Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484-92 DOI: 10.1002/art.10947
Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107:3925-32 DOI: 10.1182/blood-2005-11-4502
Iikuni N, Lourenco EV, Hahn BH, La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol. 2009;183:1518-22 DOI: 10.4049/jim-munol.0901163
Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601 DOI: 10.1016/j.immu-ni.2004.09.002
Seo SJ, Fields ML, Buckler JL, et al. The impact of T helper and T regulatory cells on the regulation of anti-double stranded DNA B cells. Immunity. 2002;16:535-46 DOI: 10.1016/S1074-7613(02)00298-4
Morgan ME, Sutmuller RP, Witteveen HJ, et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 2003;48:1452-60 DOI: 10.1002/art.11063
Jang E, Cho W, Cho M, et al. Foxp3+ Regulatory T Cells Control Humoral Autoimmunity by Suppressing the Development of Long-Lived Plasma Cells. J Immunol. 2011;186:1546-53 DOI: 10.4049/jimmunol.1002942
Hunt L, Hensor EM, Nam J, et al. T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals. Ann Rheum Dis. 2016;75:1884-9 DOI: 10.1136/annrheumdis-2015-207991
Janssen K, Westra J, Chalan P, et al. Regulatory CD4+ T-Cell Subsets and AntiCitrullinated Protein Antibody Repertoire: Potential Biomarkers for Arthritis Development in Seropositive Arthralgia Patients? PLoS ONE 2016;11(9):e0162101 DOI: 10.1371/journal.pone.0162101PLoS

Еще

Статья научная